StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Summit Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Summit Therapeutics's price to book ratio was 20.9× on Nov 11, 2026, against 69.3× a year earlier. Over the last 5 years it ranged from 1.2× to 171.5×, with a median of 20.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202620.9×−46.8
2025Dec 31, 202567.7×+37.7
2024Dec 31, 202430.0×+11.7
2023Dec 29, 202318.3×+11.9
2022Dec 30, 20226.4×+3.9
2021Dec 31, 20212.6×+1.2
2020Dec 31, 20201.4×+0.9
2019Dec 31, 20190.5×–

More Summit Therapeutics figures

See a number that looks wrong?